Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Switch Environment Makes U.K. A Sound Warm-up For Centralized Switch

This article was originally published in The Tan Sheet

Executive Summary

The U.K.'s bullish Rx-to-OTC switch environment can make it an attractive place to try a switch before pursuing the EU-wide centralized procedure, which contains more potential pitfalls, experts say
Advertisement

Related Content

OTC Oxytrol Approval In U.S. Highlights European Switch Struggles
OTC Oxytrol Approval In U.S. Highlights European Switch Struggles
OTC Oxytrol Approval In U.S. Highlights European Switch Struggles
OTC Oxytrol Approval In U.S. Highlights European Switch Struggles
Crestor Indication Grows User Pool, But Self-Selection Hinders Statin Switch
Centralized Switch Can Be Improved Via Practice, Practical Strategy
European OTC Industry Prescribes Key Role For Pharmacists
Pfizer Pulls Back On European Viagra Switch As Questions Linger
OTC statins
UK Switch Plan Questioned As European Role Model

Topics

Advertisement
UsernamePublicRestriction

Register

PS103375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel